IRON Financial LLC Purchases 68 Shares of Johnson & Johnson $JNJ

IRON Financial LLC grew its stake in Johnson & Johnson (NYSE:JNJFree Report) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,646 shares of the company’s stock after purchasing an additional 68 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of IRON Financial LLC’s investment portfolio, making the stock its 25th largest holding. IRON Financial LLC’s holdings in Johnson & Johnson were worth $1,626,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $35,000. Highline Wealth Partners LLC grew its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $48,000. Finally, von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $49,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.1%

Shares of NYSE JNJ opened at $190.88 on Tuesday. The company has a 50 day simple moving average of $178.88 and a 200 day simple moving average of $163.97. The firm has a market cap of $459.71 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Barclays increased their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Citigroup increased their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. HSBC increased their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $192.94.

Get Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.